Allison Luo
Technik-/Wissenschafts-/F&E-Leiter bei PROMETHEUS BIOSCIENCES, INC.
Aktive Positionen von Allison Luo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PROMETHEUS BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2018 | - |
| BIORA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.06.2017 | - |
Karriereverlauf von Allison Luo
Ehemalige bekannte Positionen von Allison Luo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Direktor/Vorstandsmitglied | 01.09.2006 | 01.10.2014 |
| IVERIC BIO, INC. | Corporate Officer/Principal | 01.09.2015 | - |
| ABBOTT LABORATORIES | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Allison Luo
| Northwestern University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 2 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIORA THERAPEUTICS, INC. | Health Services |
| Private Unternehmen | 2 |
|---|---|
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. BiotechnologyHealth Technology Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA . | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
- Börse
- Insiders
- Allison Luo
- Erfahrung